Coronary In-Stent Restenosis – Current Perspectives
A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425).
Deadline for manuscript submissions: 30 June 2024 | Viewed by 190
Special Issue Editors
2. Medical Faculty, University of Ostrava, 70833 Ostrava, Czech Republic
Interests: in-stent restenosis; drug-eluting balloon catheters; chronic total occlusion
2. Center for Interventional Neuroradiology and Endovascular Therapy, Bratislava, Slovak Republic
3. Univmed s.r.o., Brno, Czech Republic
Interests: acute coronary syndrome; interventional cardiology; endovascular therapy; PCI; intravascular coronary lithotripsy; coronary atherectomy; coronary imaging; left ventricular mechanical support system Pulsecath
Special Issue Information
Dear Colleagues,
Percutaneous coronary intervention (PCI), which allows the removal of coronary obstruction and restoration of supply to the affected myocardium, has brought major improvements in the treatment of coronary artery disease. The introduction of coronary stent implantation as a routine part of the interventional procedure was a breakthrough that improved early periprocedural and long-term clinical outcomes of PCI. Coronary stents allowed management of early periprocedural complications and led to a lower occurrence of restenosis following the plane balloon angioplasty due to the restricted elastic recoil and constrictive remodelling. The development of neointimal hyperplasia is, however, a novel complication associated with stent implantation possibly causing, recurrence of the narrowing of the vessel lumen, the so-called in-stent restenosis (ISR). Although the use of drug-eluting stents (DES) contributed to their lower occurrence, in-stent restenosis remains one of the essential limitations of coronary interventions. In addition, the restenosis in drug-eluting stent (DES-ISR), so called "DES-failure", is a complex process involving not only the intrinsic reaction of the vessel wall to the metallic stent platform, but also the biocompatibility of the polymer coating or insufficient effect of the antiproliferative drug, making the treatment of these remaining DES-ISR even more challenging. The aim of the present special issue is to provide a clear overview on contemporary trends in the in-stent restenosis diagnostics and treatment.
Dr. Leoš Pleva
Dr. Ota Hlinomaz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- in-stent restenosis
- drug-eluting stent
- paclitaxel-eluting balloon catheter
- sirolimus-eluting balloon catheters
